Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
11 03 2019
Historique:
received: 14 11 2018
accepted: 18 02 2019
entrez: 13 3 2019
pubmed: 13 3 2019
medline: 21 10 2020
Statut: epublish

Résumé

Over the past decade, cold atmospheric plasmas have shown promising application in cancer therapy. The therapeutic use of plasma-activated media is a topic addressed in an emerging field known as plasma pharmacy. In oncology, plasma-activated media are  used to harness the therapeutic effects of oxidant species when they come in contact with cancer cells. Among several factors that contribute to the anticancer effect of plasma-activated liquid media (PALM), H

Identifiants

pubmed: 30858524
doi: 10.1038/s41598-019-40637-z
pii: 10.1038/s41598-019-40637-z
pmc: PMC6411873
doi:

Substances chimiques

CALR protein, human 0
Calreticulin 0
Culture Media 0
Nitrites 0
Plasma Gases 0
Hydrogen Peroxide BBX060AN9V

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4099

Références

Curr Opin Immunol. 2015 Apr;33:23-35
pubmed: 25621841
Free Radic Biol Med. 2011 Aug 1;51(3):576-93
pubmed: 21619929
Nat Rev Drug Discov. 2008 Feb;7(2):156-67
pubmed: 18167491
Front Immunol. 2016 Mar 29;7:110
pubmed: 27066003
Int J Dev Biol. 2015;59(1-3):131-40
pubmed: 26374534
Genes Immun. 2019 Jul;20(6):509-513
pubmed: 30282994
Ann Surg Oncol. 2018 Jan;25(1):299-307
pubmed: 29139022
Autophagy. 2012 Mar;8(3):413-5
pubmed: 22361584
Cell Mol Life Sci. 2018 Jan;75(2):225-240
pubmed: 28744671
Nat Med. 2015 Oct;21(10):1209-15
pubmed: 26322579
Sci Rep. 2016 Apr 01;6:23737
pubmed: 27033381
Springerplus. 2014 Jul 31;3:398
pubmed: 25184103
Free Radic Biol Med. 2010 Mar 15;48(6):749-62
pubmed: 20045723
Science. 2011 Dec 16;334(6062):1573-7
pubmed: 22174255
Oncoimmunology. 2014 Dec 13;3(9):e955691
pubmed: 25941621
PLoS One. 2018 Jan 11;13(1):e0191311
pubmed: 29324830
Immunol Rev. 2017 Nov;280(1):126-148
pubmed: 29027218
Methods Mol Biol. 2008;445:77-88
pubmed: 18425443
Lasers Med Sci. 2018 Aug;33(6):1335-1340
pubmed: 29611065
Drugs. 2018 Aug;78(12):1197-1209
pubmed: 30097888
Biochem Pharmacol. 2018 Jul;153:12-23
pubmed: 29438676
Front Immunol. 2018 Aug 15;9:1878
pubmed: 30158932
Immunol Lett. 2018 Jan;193:25-34
pubmed: 29175313
Nat Rev Dis Primers. 2016 Apr 21;2:16022
pubmed: 27158978
Free Radic Biol Med. 2015 Feb;79:28-44
pubmed: 25433364
Biochim Biophys Acta. 2016 Nov;1863(11):2710-2718
pubmed: 27542908
ACS Biomater Sci Eng. 2015 Feb 9;1(2):64-78
pubmed: 25984571
Plasma Med. 2016;6(2):135-177
pubmed: 28428835
Cell Death Dis. 2013 Dec 12;4:e966
pubmed: 24336086
Sci Rep. 2017 Nov 28;7(1):16478
pubmed: 29184131
PLoS One. 2013 Dec 18;8(12):e81576
pubmed: 24367486
Oncoimmunology. 2018 Jul 26;7(9):e1484978
pubmed: 30228954
Redox Biol. 2016 Oct;9:1-14
pubmed: 27236086
Nat Rev Cancer. 2012 Dec;12(12):860-75
pubmed: 23151605
Sci Rep. 2017 Jun 30;7(1):4479
pubmed: 28667316
World J Gastroenterol. 2016 Mar 7;22(9):2678-700
pubmed: 26973408
World J Gastroenterol. 2018 May 28;24(20):2137-2151
pubmed: 29853732
Tumour Biol. 2016 Jun;37(6):7021-31
pubmed: 26888782
J Biol Regul Homeost Agents. 2013 Jan-Mar;27(1):131-41
pubmed: 23489693
Proc Natl Acad Sci U S A. 1928 Aug;14(8):627-37
pubmed: 16587379
EMBO J. 2009 Mar 4;28(5):578-90
pubmed: 19165151
Adv Ther. 2016 Jun;33(6):894-909
pubmed: 27142848
J Mol Biol. 2010 Sep 3;401(5):799-812
pubmed: 20624402
Oncogene. 2016 Nov 17;35(46):5931-5941
pubmed: 27086930
Gastric Cancer. 2015 Jul;18(3):635-43
pubmed: 24997570
Sci Rep. 2015 Dec 17;5:18339
pubmed: 26677750
Immunol Lett. 2015 Apr;164(2):65-71
pubmed: 25721381
Front Immunol. 2015 Aug 07;6:402
pubmed: 26300886
Biol Chem. 2018 Dec 19;400(1):39-62
pubmed: 30044757
Int J Mol Sci. 2017 May 03;18(5):
pubmed: 28467380
Cell Death Differ. 2015 Mar;22(3):377-88
pubmed: 25257172
Trends Cancer. 2017 Sep;3(9):643-658
pubmed: 28867168
Pharmazie. 2013 Jul;68(7):492-8
pubmed: 23923628
Oncotarget. 2017 Feb 28;8(9):15977-15995
pubmed: 27845910

Auteurs

Amalia Azzariti (A)

Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Viale O. Flacco, 65, 70124, Bari, Italy. a.azzariti@oncologico.bari.it.

Rosa Maria Iacobazzi (RM)

Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Viale O. Flacco, 65, 70124, Bari, Italy.

Roberta Di Fonte (R)

Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Viale O. Flacco, 65, 70124, Bari, Italy.

Letizia Porcelli (L)

Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Viale O. Flacco, 65, 70124, Bari, Italy.

Roberto Gristina (R)

Institute of Nanotechnology, National Research Council of Italy (CNR-NANOTEC), c/o Department of Chemistry, University of Bari "Aldo Moro" via Orabona 4, Bari, 70126, Italy.

Pietro Favia (P)

Institute of Nanotechnology, National Research Council of Italy (CNR-NANOTEC), c/o Department of Chemistry, University of Bari "Aldo Moro" via Orabona 4, Bari, 70126, Italy.
Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari Aldo Moro via Orabona 4, Bari, 70126, Italy.

Francesco Fracassi (F)

Institute of Nanotechnology, National Research Council of Italy (CNR-NANOTEC), c/o Department of Chemistry, University of Bari "Aldo Moro" via Orabona 4, Bari, 70126, Italy.
Department of Chemistry, University of Bari Aldo Moro Via Orabona 4, Bari, 70126, Italy.

Ilaria Trizio (I)

Department of Chemistry, University of Bari Aldo Moro Via Orabona 4, Bari, 70126, Italy.

Nicola Silvestris (N)

Scientific Direction, IRCCS Istituto Tumori Giovanni Paolo II, Viale O. Flacco, 65, 70124, Bari, Italy.

Gabriella Guida (G)

Department of Basic Medical Sciences, Neurosciences and Sense Organs -University of Bari Aldo Moro via Orabona 4, Bari, 70126, Italy.

Stefania Tommasi (S)

Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori Giovanni Paolo II, Viale O. Flacco, 65, 70124, Bari, Italy.

Eloisa Sardella (E)

Institute of Nanotechnology, National Research Council of Italy (CNR-NANOTEC), c/o Department of Chemistry, University of Bari "Aldo Moro" via Orabona 4, Bari, 70126, Italy. eloisa.sardella@cnr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH